W. Messersmith

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Jaap Verweij, G. Cusatis, RH van Schaik et al. · Clinical Pharmacology & Therapeutics · 2008 · 170 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Bert H. O’Neil, Aaron J. Scott, W.W. Ma et al. · Annals of Oncology · 2015 · 141 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors

Ross C. Donehower, Antonio Jimeno, J. Li et al. · Journal of Clinical Oncology · 2006 · 17 citations

Medicine, Pharmacokinetics, Pharmacology +16

A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma

Dawn Thompson, K. T. Flaherty, W. Messersmith et al. · Journal of Clinical Oncology · 2009 · 13 citations

Medicine, Oncology, Pharmacology +14